COR Cencora
- Official Name: Cencora, Inc.
- Headquarters: 1 West First Avenue, CONSHOHOCKEN, PA, 19428 US
- CEO: Robert P. Mauch
- Website: amerisourcebergen.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1R | Lost by 0.359 | (0.443) - (0.084) | ||
| 2025-07-17 | 1 | Lost by 2.578 | (1.163) - 1.415 | ||
| 2025-07-24 | 2 | Lost by 1.552 | (2.004) - (0.452) | ||
| 2025-07-31 | 3 | Lost by 7.913 | (4.017) - 3.896 | ||
| 2025-08-07 | 4 | Lost by 8.007 | (2.758) - 5.249 | ||
| 2025-08-07 | 1R | Lost by 1.184 | (1.215) - (0.031) | ||
| 2025-08-14 | 5 | Won by 7.757 | 6.873 - (0.884) | ||
| 2025-08-21 | 6 | Won by 4.465 | 2.446 - (2.019) | ||
| 2025-08-28 | 7 | Won by 3.000 | 3.000 - 0.000 | ||
| 2025-09-04 | 8 | Won by 1.478 | 0.923 - (0.555) | ||
| 2025-09-11 | 9 | Won by 4.364 | 3.214 - (1.150) | ||
| 2025-09-18 | 10 | Lost by 4.272 | (4.051) - 0.221 | ||
| 2025-09-25 | 11 | Won by 8.362 | 2.220 - (6.142) | ||
| 2025-10-02 | 12 | Lost by 3.812 | 3.243 - 7.055 | ||
| 2025-10-09 | 13 | Lost by 0.244 | 1.867 - 2.111 | ||
| 2025-10-16 | 14 | Lost by 3.342 | 1.825 - 5.167 | ||
| 2025-10-23 | 15 | Won by 2.606 | 3.072 - 0.466 |
Latest News

Cencora (COR): 3 Reasons We Love This Stock
Cencora has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6% to...

Is Cencora (COR) Undervalued Or Is Raised Guidance Already Priced In?
Cencora has delivered a powerful long run for shareholders, and the question now is whether the current share price lines up with the cash the busines...
UBS Maintains Buy on Cencora, Lowers Price Target to $400
UBS analyst Kevin Caliendo maintains Cencora (NYSE:COR) with a Buy and lowers the price target from $430 to $400.

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readout...

AI Disruption May Benefit Cencora More Than Hims & Hers
Cencora (COR) may gain from AI-driven prescribing volume growth; with strong operating leverage and discounted P/E, see risks and $365 targetârea...

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.